Cargando…

LARGE expression in different types of muscular dystrophies other than dystroglycanopathy

BACKGROUND: Alpha-dystroglycan (αDG) is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin globular domains and certain arenaviruses. An important enzyme, known as Like-acetylglucosaminyltransferase (LARGE), has been shown to tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Balci-Hayta, Burcu, Talim, Beril, Kale, Gulsev, Dincer, Pervin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295086/
https://www.ncbi.nlm.nih.gov/pubmed/30553274
http://dx.doi.org/10.1186/s12883-018-1207-0
_version_ 1783380841519382528
author Balci-Hayta, Burcu
Talim, Beril
Kale, Gulsev
Dincer, Pervin
author_facet Balci-Hayta, Burcu
Talim, Beril
Kale, Gulsev
Dincer, Pervin
author_sort Balci-Hayta, Burcu
collection PubMed
description BACKGROUND: Alpha-dystroglycan (αDG) is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin globular domains and certain arenaviruses. An important enzyme, known as Like-acetylglucosaminyltransferase (LARGE), has been shown to transfer repeating units of -glucuronic acid-β1,3-xylose-α1,3- (matriglycan) to αDG that is required for functional receptor as an extracellular matrix protein scaffold. The reduction in the amount of LARGE-dependent matriglycan result in heterogeneous forms of dystroglycanopathy that is associated with hypoglycosylation of αDG and a consequent lack of ligand-binding activity. Our aim was to investigate whether LARGE expression showed correlation with glycosylation of αDG and histopathological parameters in different types of muscular dystrophies, except for dystroglycanopathies. METHODS: The expression level of LARGE and glycosylation status of αDG were examined in skeletal muscle biopsies from 26 patients with various forms of muscular dystrophy [Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), sarcoglycanopathy, dysferlinopathy, calpainopathy, and merosin and collagen VI deficient congenital muscular dystrophies (CMDs)] and correlation of results with different histopathological features was investigated. RESULTS: Despite the fact that these diseases are not caused by defects of glycosyltransferases, decreased expression of LARGE was detected in many patient samples, partly correlating with the type of muscular dystrophy. Although immunolabelling of fully glycosylated αDG with VIA4–1 was reduced in dystrophinopathy patients, no significant relationship between reduction of LARGE expression and αDG hypoglycosylation was detected. Also, Merosin deficient CMD patients showed normal immunostaining with αDG despite severe reduction of LARGE expression. CONCLUSIONS: Our data shows that it is not always possible to correlate LARGE expression and αDG glycosylation in different types of muscular dystrophies and suggests that there might be differences in αDG processing by LARGE which could be regulated under different pathological conditions.
format Online
Article
Text
id pubmed-6295086
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62950862018-12-18 LARGE expression in different types of muscular dystrophies other than dystroglycanopathy Balci-Hayta, Burcu Talim, Beril Kale, Gulsev Dincer, Pervin BMC Neurol Research Article BACKGROUND: Alpha-dystroglycan (αDG) is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin globular domains and certain arenaviruses. An important enzyme, known as Like-acetylglucosaminyltransferase (LARGE), has been shown to transfer repeating units of -glucuronic acid-β1,3-xylose-α1,3- (matriglycan) to αDG that is required for functional receptor as an extracellular matrix protein scaffold. The reduction in the amount of LARGE-dependent matriglycan result in heterogeneous forms of dystroglycanopathy that is associated with hypoglycosylation of αDG and a consequent lack of ligand-binding activity. Our aim was to investigate whether LARGE expression showed correlation with glycosylation of αDG and histopathological parameters in different types of muscular dystrophies, except for dystroglycanopathies. METHODS: The expression level of LARGE and glycosylation status of αDG were examined in skeletal muscle biopsies from 26 patients with various forms of muscular dystrophy [Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), sarcoglycanopathy, dysferlinopathy, calpainopathy, and merosin and collagen VI deficient congenital muscular dystrophies (CMDs)] and correlation of results with different histopathological features was investigated. RESULTS: Despite the fact that these diseases are not caused by defects of glycosyltransferases, decreased expression of LARGE was detected in many patient samples, partly correlating with the type of muscular dystrophy. Although immunolabelling of fully glycosylated αDG with VIA4–1 was reduced in dystrophinopathy patients, no significant relationship between reduction of LARGE expression and αDG hypoglycosylation was detected. Also, Merosin deficient CMD patients showed normal immunostaining with αDG despite severe reduction of LARGE expression. CONCLUSIONS: Our data shows that it is not always possible to correlate LARGE expression and αDG glycosylation in different types of muscular dystrophies and suggests that there might be differences in αDG processing by LARGE which could be regulated under different pathological conditions. BioMed Central 2018-12-15 /pmc/articles/PMC6295086/ /pubmed/30553274 http://dx.doi.org/10.1186/s12883-018-1207-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Balci-Hayta, Burcu
Talim, Beril
Kale, Gulsev
Dincer, Pervin
LARGE expression in different types of muscular dystrophies other than dystroglycanopathy
title LARGE expression in different types of muscular dystrophies other than dystroglycanopathy
title_full LARGE expression in different types of muscular dystrophies other than dystroglycanopathy
title_fullStr LARGE expression in different types of muscular dystrophies other than dystroglycanopathy
title_full_unstemmed LARGE expression in different types of muscular dystrophies other than dystroglycanopathy
title_short LARGE expression in different types of muscular dystrophies other than dystroglycanopathy
title_sort large expression in different types of muscular dystrophies other than dystroglycanopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295086/
https://www.ncbi.nlm.nih.gov/pubmed/30553274
http://dx.doi.org/10.1186/s12883-018-1207-0
work_keys_str_mv AT balcihaytaburcu largeexpressionindifferenttypesofmusculardystrophiesotherthandystroglycanopathy
AT talimberil largeexpressionindifferenttypesofmusculardystrophiesotherthandystroglycanopathy
AT kalegulsev largeexpressionindifferenttypesofmusculardystrophiesotherthandystroglycanopathy
AT dincerpervin largeexpressionindifferenttypesofmusculardystrophiesotherthandystroglycanopathy